# INDUCOMAIN (NCT03390595)

> Avelumab Plus Carboplatin-gemcitabine in Urothelial Carcinoma

No report yet. It can be ordered.

- Drugs tested: avelumab

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03390595
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Associació per a la Recerca Oncologica, Spain
- Conditions: Metastatic Urothelial Cancer
- Interventions: avelumab 10mg/kg with carboplatin/gemcitabine; carboplatin/gemcitabine alone
- Enrollment: 85
- Primary outcome: Objective Response Rate (ORR)

## Indexed commentary on INDUCOMAIN so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=inducomain-nct03390595